Liposomal Formulations of Metallodrugs for Cancer Therapy
International Journal of Molecular Sciences · 28.08.2024 · 25 (17) · 9337
DOI: 10.3390/ijms25179337 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.08.2024. Verfasst von Eleonora Botter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Sciences and Nanosystems, Università Ca' Foscari Campus Scientifico, Via Torino 155, 30174 Venezia-Mestre, Italy. Hauptthemen laut MEDLINE: Liposomes, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AIRC, Fondazione AIRC per la Ricerca sul Cancro.
Abstract (Originalsprache)
The search for new antineoplastic agents is imperative, as cancer remains one of the most preeminent causes of death worldwide. Since the discovery of the therapeutic potential of cisplatin, the study of metallodrugs in cancer chemotherapy acquired increasing interest. Starting from cisplatin derivatives, such as oxaliplatin and carboplatin, in the last years, different compounds were explored, employing different metal centers such as iron, ruthenium, gold, and palladium. Nonetheless, metallodrugs face several drawbacks, such as low water solubility, rapid clearance, and possible side toxicity. Encapsulation has emerged as a promising strategy to overcome these issues, providing both improved biocompatibility and protection of the payload from possible degradation in the biological environment. In this respect, liposomes, which are spherical vesicles characterized by an aqueous core surrounded by lipid bilayers, have proven to be ideal candidates due to their versatility. In fact, they can encapsulate both hydrophilic and hydrophobic drugs, are biocompatible, and their properties can be tuned to improve the selective delivery to tumour sites exploiting both passive and active targeting. In this review, we report the most recent findings on liposomal formulations of metallodrugs, with a focus on encapsulation techniques and the obtained biological results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Sciences and Nanosystems, Università Ca' Foscari Campus Scientifico, Via Torino 155, 30174 Venezia-Mestre, Italy.
- Pathology Unit, Department of Molecular Biology and Translational Research, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via Franco Gallini 2, 33081 Aviano, Italy.
- Dipartimento di Scienze Chimiche, Università degli Studi di Padova, Via Marzolo 1, 35131 Padova, Italy.
ORCID-Profile: Eleonora Botter, Flavio Rizzolio, Thomas Scattolin
Förderung
- AIRC
- Fondazione AIRC per la Ricerca sul Cancro
Zitieren
APA
Botter, E., Caligiuri, I., Rizzolio, F., Visentin, F., & Scattolin, T. (2024). Liposomal Formulations of Metallodrugs for Cancer Therapy. International Journal of Molecular Sciences, 25(17), 9337. https://doi.org/10.3390/ijms25179337
Vancouver
Botter E, Caligiuri I, Rizzolio F, Visentin F, Scattolin T. Liposomal Formulations of Metallodrugs for Cancer Therapy. International Journal of Molecular Sciences. 2024;25(17):9337. doi:10.3390/ijms25179337
BibTeX
@article{Botter2024,
author = {Botter, Eleonora and Caligiuri, Isabella and Rizzolio, Flavio and Visentin, Fabiano and Scattolin, Thomas},
title = {Liposomal Formulations of Metallodrugs for Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {17},
pages = {9337},
doi = {10.3390/ijms25179337}
}
EUVIMED